期刊
CELL CYCLE
卷 10, 期 6, 页码 977-988出版社
LANDES BIOSCIENCE
DOI: 10.4161/cc.10.6.15079
关键词
melanoma; cyclin-dependent kinase expression; small-molecule inhibitor treatment; proliferation; cell cycle progression; apoptosis; tumor xenograft studies
类别
资金
- Merck Research Laboratory-Kenilworth, Kenilworth, NJ
- National Institutes of Health
A major focus of melanoma research continues to be the search for genes/proteins that may be suitable targets for molecular therapy of primary and metastatic melanoma. In line with this effort, the objective of the study presented herein was to determine whether interfering with cell cycle progression and in particular, the expression and function of select cyclin-dependent kinases, would impair the biological features of advanced melanoma. We provide data, which document that unlike nevi and melanoma in situ, primary and metastatic melanomas express high levels of CDK2, CDK1, and CDK5. Furthermore, we present the results of in vitro and preclinical in vivo studies, which demonstrate that treatment with a small-molecule cyclin-dependent kinase inhibitor that selectively blocks the function of CDK2, CDK5, CDK1 and CDK9, leads not only to inhibition of melanoma cell proliferation and apoptosis of melanoma cells, but also impairs the growth of human melanoma xenografts.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据